Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announced that CEO and Chairman John Yu, MD, will present a corporate overview in person at the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for Sept. 14-16, 2026, at the Lotte New York Palace Hotel. The presentation is expected to provide investors with an update on the company's progress and strategic direction.
Kairos Pharma is based in Los Angeles, California, and is at the forefront of oncology therapeutics, utilizing structural biology to address drug resistance and immune suppression in cancer. The company's lead candidate, ENV-105, is an antibody that targets CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. By targeting CD105, ENV-105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types.
The significance of this presentation lies in the potential impact of ENV-105 on cancer treatment paradigms. Drug resistance remains a major challenge in oncology, often leading to treatment failure and disease progression. If ENV-105 proves effective in clinical trials, it could offer a new approach to sensitize tumors to existing therapies, potentially improving outcomes for patients with various cancers. This aligns with a growing trend in oncology toward combination therapies and overcoming resistance mechanisms.
For the industry, Kairos Pharma's participation in the H.C. Wainwright conference underscores the continued interest in innovative approaches to cancer treatment. Investors and stakeholders will be keen to hear about the latest developments from the company, including any updates on ENV-105's clinical trials and future milestones. The conference provides a platform for Kairos Pharma to showcase its science and potentially attract partnerships or funding.
The broader impact of this announcement is that it brings attention to the critical issue of cancer drug resistance, which affects millions of patients worldwide. By focusing on CD105, Kairos Pharma is targeting a novel pathway that could complement existing therapies. If successful, ENV-105 could become an important addition to the oncology arsenal, offering hope for patients who have limited options due to resistance.
For more information about Kairos Pharma and its latest news, visit the company's newsroom at https://ibn.fm/KAPA. The full press release regarding the conference presentation is available at https://ibn.fm/NrBQD.
